(Q50957180)

26 March 2018

title

Adjuvant Therapy of Melanoma. (English)

1 reference

26 March 2018

author name string

Diwakar Davar

series ordinal

1

1 reference

26 March 2018

John M Kirkwood

series ordinal

2

1 reference

26 March 2018

publication date

1 January 2016

1 reference

26 March 2018

Cancer Treatment and Research

published in

1 reference

26 March 2018

volume

167

1 reference

26 March 2018

page(s)

181-208

1 reference

26 March 2018

Final version of 2009 AJCC melanoma staging and classification

cites work

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Value of sentinel node status as a prognostic factor in melanoma: prospective observational study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Isolated tumor cells and long-term prognosis of patients with melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Outcome predictors of Gamma Knife surgery for melanoma brain metastases. Clinical article

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

High-dose interferon alfa-2b does not diminish antibody response to GM2 vaccination in patients with resected melanoma: results of the Multicenter Eastern Cooperative Oncology Group Phase II Trial E2696

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Randomized phase III study of 1 month versus 1 year of adjuvant high-dose interferon alfa-2b in patients with resected high-risk melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Post-surgery adjuvant therapy with intermediate doses of interferon alfa 2b versus observation in patients with stage IIb/III melanoma (EORTC 18952): randomised controlled trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Two different durations of adjuvant therapy with intermediate-dose interferon alfa-2b in patients with high-risk melanoma (Nordic IFN trial): a randomised phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Adjuvant interferon alfa-2a treatment in resected primary stage II cutaneous melanoma. Austrian Malignant Melanoma Cooperative Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Randomised trial of interferon alpha-2a as adjuvant therapy in resected primary melanoma thicker than 1.5 mm without clinically detectable node metastases. French Cooperative Group on Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Effect of long-term adjuvant therapy with interferon alpha-2a in patients with regional node metastases from cutaneous melanoma: a randomised trial.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Adjuvant interferon alpha 2b in high risk melanoma - the Scottish study

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness >3 mm) or regional lymph node metast

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Adjuvant interferon in high-risk melanoma: the AIM HIGH Study--United Kingdom Coordinating Committee on Cancer Research randomized study of adjuvant low-dose extended-duration interferon Alfa-2a in high-risk resected malignant melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Efficacy of low-dose interferon {alpha}2a 18 versus 60 months of treatment in patients with primary melanoma of >= 1.5 mm tumor thickness: results of a randomized phase III DeCOG trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Southwest Oncology Group S0008: a phase III trial of high-dose interferon Alfa-2b versus cisplatin, vinblastine, and dacarbazine, plus interleukin-2 and interferon in patients with high-risk melanoma--an intergroup study of cancer and leukemia Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Interferon alfa therapy for malignant melanoma: a systematic review of randomized controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Interferon alpha for the adjuvant treatment of cutaneous melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Does adjuvant interferon-alpha for high-risk melanoma provide a worthwhile benefit? A meta-analysis of the randomised trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Phase II Pilot Study of Intravenous High-Dose Interferon With or Without Maintenance Treatment in Melanoma at High Risk of Recurrence

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Systematic review of medical treatment in melanoma: current status and future prospects.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Vaccines against advanced melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

DTIC and combination therapy for melanoma: III. DTIC (NSC 45388) Surgical Adjuvant Study COG PROTOCOL 7040.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Easter

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Phase III trial comparing concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin-2, and interferon alfa-2b with cisplatin, vinblastine, and dacarbazine alone in patients with metastatic malignant melanoma (E3695): a trial c

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Somatic activation of KIT in distinct subtypes of melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Mutations in KIT occur at low frequency in melanomas arising from anatomical sites associated with chronic and intermittent sun exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Large-scale analysis of KIT aberrations in Chinese patients with melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Phase II randomized trial comparing high-dose IFN-α2b with temozolomide plus cisplatin as systemic adjuvant therapy for resected mucosal melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Fraction size in external beam radiation therapy in the treatment of melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Mutations of the BRAF gene in human cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Determinants of BRAF mutations in primary melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Distinct sets of genetic alterations in melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032.

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Routine multiplex mutational profiling of melanomas enables enrollment in genotype-driven therapeutic trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Survival in BRAF V600-mutant advanced melanoma treated with vemurafenib

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Ipilimumab plus dacarbazine for previously untreated metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1007%2F978-3-319-22539-5_7

10.1007/978-3-319-22539-5_7

31 March 2020

Identifiers

DOI

1 reference

26 March 2018

1 reference

26 March 2018